Falcon Point Capital LLC increased its position in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) by 130.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,983 shares of the specialty pharmaceutical company’s stock after buying an additional 13,597 shares during the period. Falcon Point Capital LLC owned 0.09% of Paratek Pharmaceuticals worth $578,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the company. State Street Corp increased its position in Paratek Pharmaceuticals by 21.5% in the fourth quarter. State Street Corp now owns 238,092 shares of the specialty pharmaceutical company’s stock worth $3,668,000 after buying an additional 42,117 shares in the last quarter. Norges Bank bought a new position in Paratek Pharmaceuticals during the fourth quarter worth $1,486,000. Teachers Advisors LLC increased its position in Paratek Pharmaceuticals by 1.1% in the fourth quarter. Teachers Advisors LLC now owns 25,363 shares of the specialty pharmaceutical company’s stock worth $391,000 after buying an additional 270 shares in the last quarter. Candriam Luxembourg S.C.A. bought a new position in Paratek Pharmaceuticals during the first quarter worth $2,310,000. Finally, Russell Investments Group Ltd. bought a new position in Paratek Pharmaceuticals during the first quarter worth $211,000. 77.96% of the stock is currently owned by institutional investors.

Paratek Pharmaceuticals, Inc. (PRTK) opened at 19.80 on Monday. The stock’s market cap is $549.67 million. Paratek Pharmaceuticals, Inc. has a 52 week low of $9.80 and a 52 week high of $26.10. The stock has a 50 day moving average of $22.39 and a 200-day moving average of $19.95.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.89) by $0.25. The business had revenue of $7.51 million during the quarter, compared to the consensus estimate of $7.50 million.

TRADEMARK VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/14/paratek-pharmaceuticals-inc-nasdaqprtk-stake-boosted-by-falcon-point-capital-llc.html.

PRTK has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $24.00 price target on the stock in a research note on Thursday, April 20th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $32.00 price target on shares of Paratek Pharmaceuticals in a research note on Monday, April 24th. Raymond James Financial, Inc. initiated coverage on shares of Paratek Pharmaceuticals in a research note on Thursday, May 18th. They set a “strong-buy” rating and a $36.00 price target on the stock. HC Wainwright increased their price target on shares of Paratek Pharmaceuticals from $36.00 to $43.00 and gave the stock a “buy” rating in a research note on Tuesday, July 18th. Finally, BidaskClub downgraded shares of Paratek Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 24th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $37.44.

In other Paratek Pharmaceuticals news, COO Evan Loh sold 4,351 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $23.58, for a total value of $102,596.58. Following the completion of the sale, the chief operating officer now directly owns 112,783 shares of the company’s stock, valued at $2,659,423.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Adam Woodrow sold 3,800 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The stock was sold at an average price of $23.58, for a total transaction of $89,604.00. Following the completion of the sale, the vice president now directly owns 69,500 shares of the company’s stock, valued at $1,638,810. The disclosure for this sale can be found here. Insiders sold 21,960 shares of company stock valued at $524,342 over the last three months. Insiders own 4.90% of the company’s stock.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK).

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Stock Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.